if they can sort out their issues with reinstatment to the ASX...

if they can sort out their issues with reinstatment to the ASX there should be a lot of positive news associated with the re-listing:
- merger agreement
- commercial agreement re needle free technology
- commercial agreement re eyecare technology
- $5m euro injection including a 1p/share dividend (say ~ 2c AUS) not bad seeing they last traded at 0.6c

if only NAL could manage to "do a PRR" on re-listing, here's hoping they sort themselves out so they can re-list in May as advised.